What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease?: A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel

M. Gul; B. Luca; Konstantinos Dimitropoulos; P. Capogrosso; U. Milenkovic; A. Cocci; Rajan Veeratterapillay; G. Hatzichristodoulou; V. Modgil; G. I. Russo; Tharu Tharakan; A Kalkanli; Muhammad Imran Omar; Carlo Bettocchi; Joana Carvalho; Giovanni Corona; T. H. Jones; Aras Kadioglu; J. I. Martinez-Salamanca; Ege C. Serefoglu; Paolo Verze; S. Minhas; Andrea Salonia; EAU Working Group on Sexual and Reproductive Health

doi:10.1038/s41443-022-00590-4

What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel

M. Gul, B. Luca, Konstantinos Dimitropoulos, P. Capogrosso, U. Milenkovic, A. Cocci, Rajan Veeratterapillay, G. Hatzichristodoulou, V. Modgil, G. I. Russo, Tharu Tharakan, A Kalkanli , Muhammad Imran Omar, Carlo Bettocchi, Joana Carvalho, Giovanni Corona, T. H. Jones, Aras Kadioglu, J. I. Martinez-Salamanca, Ege C. SerefogluPaolo Verze, S. Minhas, Andrea Salonia^* (Corresponding Author), EAU Working Group on Sexual and Reproductive Health

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

5 Downloads (Pure)

Abstract

Sickle cell disease (SCD) is an inherited hemoglobin disorder characterized by the occlusion of small blood vessels by sickle-shaped red blood cells. SCD and is associated with a number of complications, including ischemic priapism. While SCD accounts for at least one-third of all priapism cases, no definitive treatment strategy has been established to specifically treat patients with SC priapism. This aim of this systematic review was to assess the efficacy and safety of contemporary treatment modalities for acute and stuttering ischemic priapism associated with SCD. The primary outcome measures were defined as resolution of acute priapism (detumescence) and complete response of stuttering priapism, while the primary harm outcome was as sexual dysfunction. The protocol for the review has been registered (PROSPERO Nr: CRD42020182001), and a systematic search of Medline, Embase, and Cochrane controlled trials databases was performed. Three trials with 41 observational studies met the criteria for inclusion in this review. None of the trials assessed detumescence, as a primary outcome. All of the trials reported a complete response of stuttering priapism; however, the certainty of the evidence was low. It is clear that assessing the effectiveness of specific interventions for priapism in SCD, well-designed, adequately-powered, multicenter trials are strongly required.

Original language	English
Pages (from-to)	20-35
Number of pages	16
Journal	International Journal of Impotence Research
Volume	36
Issue number	1
Early online date	8 Aug 2022
DOIs	https://doi.org/10.1038/s41443-022-00590-4
Publication status	Published - 1 Feb 2024

Bibliographical note

The authors acknowledge the participants for their cooperation conflict of Interest: None of the authors declare any interest.
Formatting of funding sources: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data Availability Statement

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Keywords

Sickle cell disease
ischemic priapism
stuttering priapism
Erectile dysfunction

Access to Document

10.1038/s41443-022-00590-4Licence: Unspecified

Gul_etal_IJIR_What_is_that_AAM
This is the accepted version of Gül, M., Luca, B., Dimitropoulos, K. et al. What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel. Int J Impot Res (2022) version of record can be found at https://www.nature.com/articles/s41443-022-00590-4
Accepted author manuscript, 181 KBLicence: Unspecified

Fingerprint

Dive into the research topics of 'What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel'. Together they form a unique fingerprint.

Cite this

Gul, M., Luca, B., Dimitropoulos, K., Capogrosso, P., Milenkovic, U., Cocci, A., Veeratterapillay, R., Hatzichristodoulou, G., Modgil, V., Russo, G. I., Tharakan, T., Kalkanli , A., Omar, M. I., Bettocchi, C., Carvalho, J., Corona, G., Jones, T. H., Kadioglu, A., Martinez-Salamanca, J. I., ... EAU Working Group on Sexual and Reproductive Health (2024). What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel. International Journal of Impotence Research, 36(1), 20-35. https://doi.org/10.1038/s41443-022-00590-4

What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel. / Gul, M.; Luca, B.; Dimitropoulos, Konstantinos et al.
In: International Journal of Impotence Research, Vol. 36, No. 1, 01.02.2024, p. 20-35.

Research output: Contribution to journal › Article › peer-review

Gul, M, Luca, B, Dimitropoulos, K, Capogrosso, P, Milenkovic, U, Cocci, A, Veeratterapillay, R, Hatzichristodoulou, G, Modgil, V, Russo, GI, Tharakan, T, Kalkanli , A, Omar, MI, Bettocchi, C, Carvalho, J, Corona, G, Jones, TH, Kadioglu, A, Martinez-Salamanca, JI, Serefoglu, EC, Verze, P, Minhas, S, Salonia, A & EAU Working Group on Sexual and Reproductive Health 2024, 'What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel', International Journal of Impotence Research, vol. 36, no. 1, pp. 20-35. https://doi.org/10.1038/s41443-022-00590-4

Gul M, Luca B, Dimitropoulos K, Capogrosso P, Milenkovic U, Cocci A et al. What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel. International Journal of Impotence Research. 2024 Feb 1;36(1):20-35. Epub 2022 Aug 8. doi: 10.1038/s41443-022-00590-4

@article{fd2f2fe916094cc7a81f0d81702dedc5,

title = "What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease?: A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel",

abstract = "Sickle cell disease (SCD) is an inherited hemoglobin disorder characterized by the occlusion of small blood vessels by sickle-shaped red blood cells. SCD and is associated with a number of complications, including ischemic priapism. While SCD accounts for at least one-third of all priapism cases, no definitive treatment strategy has been established to specifically treat patients with SC priapism. This aim of this systematic review was to assess the efficacy and safety of contemporary treatment modalities for acute and stuttering ischemic priapism associated with SCD. The primary outcome measures were defined as resolution of acute priapism (detumescence) and complete response of stuttering priapism, while the primary harm outcome was as sexual dysfunction. The protocol for the review has been registered (PROSPERO Nr: CRD42020182001), and a systematic search of Medline, Embase, and Cochrane controlled trials databases was performed. Three trials with 41 observational studies met the criteria for inclusion in this review. None of the trials assessed detumescence, as a primary outcome. All of the trials reported a complete response of stuttering priapism; however, the certainty of the evidence was low. It is clear that assessing the effectiveness of specific interventions for priapism in SCD, well-designed, adequately-powered, multicenter trials are strongly required.",

keywords = "Sickle cell disease, ischemic priapism, stuttering priapism, Erectile dysfunction",

author = "M. Gul and B. Luca and Konstantinos Dimitropoulos and P. Capogrosso and U. Milenkovic and A. Cocci and Rajan Veeratterapillay and G. Hatzichristodoulou and V. Modgil and Russo, {G. I.} and Tharu Tharakan and A Kalkanli and Omar, {Muhammad Imran} and Carlo Bettocchi and Joana Carvalho and Giovanni Corona and Jones, {T. H.} and Aras Kadioglu and Martinez-Salamanca, {J. I.} and Serefoglu, {Ege C.} and Paolo Verze and S. Minhas and Andrea Salonia and {EAU Working Group on Sexual and Reproductive Health}",

note = "The authors acknowledge the participants for their cooperation conflict of Interest: None of the authors declare any interest. Formatting of funding sources: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.",

year = "2024",

month = feb,

day = "1",

doi = "10.1038/s41443-022-00590-4",

language = "English",

volume = "36",

pages = "20--35",

journal = "International Journal of Impotence Research",

issn = "0955-9930",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease?

T2 - A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel

AU - Gul, M.

AU - Luca, B.

AU - Dimitropoulos, Konstantinos

AU - Capogrosso, P.

AU - Milenkovic, U.

AU - Cocci, A.

AU - Veeratterapillay, Rajan

AU - Hatzichristodoulou, G.

AU - Modgil, V.

AU - Russo, G. I.

AU - Tharakan, Tharu

AU - Kalkanli , A

AU - Omar, Muhammad Imran

AU - Bettocchi, Carlo

AU - Carvalho, Joana

AU - Corona, Giovanni

AU - Jones, T. H.

AU - Kadioglu, Aras

AU - Martinez-Salamanca, J. I.

AU - Serefoglu, Ege C.

AU - Verze, Paolo

AU - Minhas, S.

AU - Salonia, Andrea

AU - EAU Working Group on Sexual and Reproductive Health

N1 - The authors acknowledge the participants for their cooperation conflict of Interest: None of the authors declare any interest. Formatting of funding sources: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

PY - 2024/2/1

Y1 - 2024/2/1

N2 - Sickle cell disease (SCD) is an inherited hemoglobin disorder characterized by the occlusion of small blood vessels by sickle-shaped red blood cells. SCD and is associated with a number of complications, including ischemic priapism. While SCD accounts for at least one-third of all priapism cases, no definitive treatment strategy has been established to specifically treat patients with SC priapism. This aim of this systematic review was to assess the efficacy and safety of contemporary treatment modalities for acute and stuttering ischemic priapism associated with SCD. The primary outcome measures were defined as resolution of acute priapism (detumescence) and complete response of stuttering priapism, while the primary harm outcome was as sexual dysfunction. The protocol for the review has been registered (PROSPERO Nr: CRD42020182001), and a systematic search of Medline, Embase, and Cochrane controlled trials databases was performed. Three trials with 41 observational studies met the criteria for inclusion in this review. None of the trials assessed detumescence, as a primary outcome. All of the trials reported a complete response of stuttering priapism; however, the certainty of the evidence was low. It is clear that assessing the effectiveness of specific interventions for priapism in SCD, well-designed, adequately-powered, multicenter trials are strongly required.

AB - Sickle cell disease (SCD) is an inherited hemoglobin disorder characterized by the occlusion of small blood vessels by sickle-shaped red blood cells. SCD and is associated with a number of complications, including ischemic priapism. While SCD accounts for at least one-third of all priapism cases, no definitive treatment strategy has been established to specifically treat patients with SC priapism. This aim of this systematic review was to assess the efficacy and safety of contemporary treatment modalities for acute and stuttering ischemic priapism associated with SCD. The primary outcome measures were defined as resolution of acute priapism (detumescence) and complete response of stuttering priapism, while the primary harm outcome was as sexual dysfunction. The protocol for the review has been registered (PROSPERO Nr: CRD42020182001), and a systematic search of Medline, Embase, and Cochrane controlled trials databases was performed. Three trials with 41 observational studies met the criteria for inclusion in this review. None of the trials assessed detumescence, as a primary outcome. All of the trials reported a complete response of stuttering priapism; however, the certainty of the evidence was low. It is clear that assessing the effectiveness of specific interventions for priapism in SCD, well-designed, adequately-powered, multicenter trials are strongly required.

KW - Sickle cell disease

KW - ischemic priapism

KW - stuttering priapism

KW - Erectile dysfunction

U2 - 10.1038/s41443-022-00590-4

DO - 10.1038/s41443-022-00590-4

M3 - Article

C2 - 35941221

AN - SCOPUS:85136803833

SN - 0955-9930

VL - 36

SP - 20

EP - 35

JO - International Journal of Impotence Research

JF - International Journal of Impotence Research

IS - 1

ER -